some confirmation and it may get it at Jackson Hole. If the chair uses that platform to set the table I want to move and talk about the stock of the day because it's Palantir and it is at a record high. After beating on earnings, surpassing $1 billion in quarterly revenue for the first time ever.The stock has just ripped. We've mentioned it on so many occasions because of what's happened in the high beta universe, where most of those stocks have ripped, but this is the one that investors have continued to z ...

Palantir is destroying their critics.$1 billion in quarterly revenue and leadership says more revenue is on the way with less employees.$PLTR https://t.co/aOj3bMbkZt ...

周二，Palantir(PLTR.US)股价触及历史新高，截至发稿，该股涨超8.6%，报174.5美元。消息面上， Palantir第二季度营收同比大增48%，首次突破10亿美元大关，连续第八个季度实现营收加速增长。 ...

Financial Data and Key Metrics Changes - Revenue for Q2 2025 grew by 7% to $36 million, with gross margins expanding by 574 basis points to 55.2% [4][15] - Adjusted EBITDA increased by 32% year over year to $8 million, with an EBITDA margin improvement of 427 basis points to 22.3% [4][18] - Net income surged by 262%, and cash flows from operations more than doubled for both the quarter and year to date [4][5] Business Line Data and Key Metrics Changes - Patient Services segment revenue increased by $1.2 million or 6.5%, driven by oncology and wound care, while pain management saw a decrease of approximately $300,000 [15][16] - Wound care revenue rose by 117% to $1.3 million, primarily due to volume increases in negative pressure wound therapy treatments [16] - Device Solutions revenue increased by $1 million or 8.3%, attributed to higher rental revenues and increased equipment sales [15][16] Market Data and Key Metrics Changes - The relationship with Smith and Nephew is progressing, with revenue from this program totaling $1.6 million in the first half of 2025 [7] - Oncology continues to contribute to steady growth, prompting an increase in the outlook for that business [8] Company Strategy and Development Direction - The company is focusing on growing profitable revenue and may restructure or exit underperforming businesses [24] - Strategic priorities include executing with discipline, delivering profitable growth, and driving long-term value creation for shareholders [26] - The company is investing in a new ERP system, which is expected to improve productivity and margins in the long term [10][25] Management's Comments on Operating Environment and Future Outlook - Management updated the 2025 revenue growth outlook to a range of 6% to 8%, down from 8% to 10% due to delays in advanced wound care volume increases and changes in the ChemoMouthpiece reimbursement landscape [9][12] - Despite the lower revenue guidance, the outlook for adjusted EBITDA has been raised, indicating confidence in operational efficiencies [9][10] Other Important Information - The company returned approximately $3.5 million to shareholders through stock repurchases during the quarter, totaling $6.4 million for the first half of the year [5] - Operating cash flow for the first six months of 2025 was $8.7 million, an increase of $6 million over the prior year [5] Q&A Session Summary Question: Oncology growth expectations - Management believes mid-single-digit growth is reasonable for the oncology business moving forward [28][29] Question: GE contract size and impact - The GE contract is currently a $7 million to $8 million business, with efforts underway to improve margins [30][31] Question: Acquisition of Apollo's impact - The acquisition will initially focus on wound care but is expected to benefit the broader platform over time [32] Question: ERP system progress - The ERP project is in the blueprint stage, with expectations to go live in 2026, and costs are projected to be around $2.5 million annually [34][35] Question: Sustainability of operating margins - Management indicated that while margins have improved, they may fluctuate based on product mix and other factors [50][51] Question: ChemoMouthpiece reimbursement timeline - Updates on reimbursement challenges for ChemoMouthpiece are expected by the end of the year [60][61]

What are the three things most likely to boost a company’s revenue? https://t.co/GRaPkS2PvZ https://t.co/GRaPkS2PvZ ...

Financial Performance - Total revenue for Q2 2025 was $1,553 million, with underlying revenue growth of +6.7% and reported growth of +7.8%[13] - H1 2025 revenue reached $2,961 million, a 4.7% reported growth compared to $2,827 million in H1 2024[36] - H1 2025 trading profit margin was 17.7%, a +100 bps expansion compared to 16.7% in H1 2024[36] - Adjusted Earnings Per Share (EPSA) for H1 2025 was 42.9¢, a 14.1% increase from 37.6¢ in H1 2024[47] - Free cash flow for H1 2025 was $244 million, significantly improved from $39 million in H1 2024[53] Business Segment Performance - Orthopaedics revenue in Q2 2025 was $615 million, with underlying growth of +5.0%[16] - Sports Medicine & ENT revenue in Q2 2025 was $479 million, with underlying growth of +5.7%[19] - Advanced Wound Management (AWM) revenue in Q2 2025 was $459 million, with underlying growth of +10.2%[27] Regional Performance - US revenue in Q2 2025 grew by +8.7% to $827 million[13] - Emerging Markets revenue in Q2 2025 decreased by -0.2% to $256 million, but grew +12.2% excluding China[13] Strategic Initiatives - A $500 million share buyback is planned for H2 2025, funded by 2025 cash flow and existing balances[9] - The company is targeting total gross run-rate savings of approximately $325-375 million in 2027 through efficiency opportunities[44]

Summary of Conference Call on China Education Sector Industry Overview - The conference call focuses on the China education industry, specifically comparing TAL Education Group (TAL) and New Oriental Education & Technology (EDU) [6][8]. Key Points on TAL Education Group (TAL) - **Revenue Growth and Margins**: TAL is expected to have a better setup for FY26 compared to EDU, with deferred revenue growing by 52% year-over-year (YoY) in F1Q26, indicating strong growth potential for FY26 [8][11]. - **Shareholder Returns**: TAL repurchased approximately US$477.4 million worth of shares in F1Q26, which is about 7% of its market cap, at an average price of US$10.5. A new buyback program of US$600 million was also announced [8][11]. - **Valuation**: TAL trades at 19.3x F27 PE and 8.1x F27 ex-cash PE, with projected revenue and net profit compound annual growth rates (CAGR) of 21% and 40% respectively over FY26-29 [8][11]. Key Points on New Oriental Education & Technology (EDU) - **Revenue Guidance**: EDU's revenue guidance for F1Q26 is +2-5% and +5-10% for FY26, which is below market expectations due to a weaker overseas business outlook and a higher base in the educational business [8][10]. - **Operational Profit Margin (OPM)**: Management guided for OPM to increase by 0-0.5 percentage points YoY for F1Q26, but expects a flat OPM for FY26 due to cost control efforts being offset by margin drag from overseas business [8][10]. - **Shareholder Returns**: EDU announced a three-year recurrent shareholder return plan to return no less than 50% of GAAP net income, implying at least US$186 million in FY26, which is lower than the US$500 million returned in FY25 [8][10]. Comparative Analysis - **Investment Preference**: Morgan Stanley prefers TAL (Overweight) over EDU (Equal-Weight) in the China education sector due to TAL's stronger revenue growth and margin trends [8][10]. - **Market Expectations**: TAL's performance is seen as more favorable compared to EDU, which is struggling with lower revenue guidance and operational challenges [8][10]. Additional Insights - **Risks**: Potential risks for both companies include intensified competition, regulatory changes in high school and non-academic tutoring, and the visibility of revenue from live-streaming e-commerce businesses [15][16]. - **Market Sentiment**: The overall sentiment towards the China education industry remains attractive, with expectations for market share gains and earnings growth potential for both TAL and EDU [6][8]. This summary encapsulates the essential insights from the conference call regarding TAL and EDU, highlighting their financial performance, shareholder return strategies, and market positioning within the China education sector.

Financial Data and Key Metrics Changes - Worldwide revenue for Q2 2025 was $48.6 million, representing a growth of 21.7% year-over-year [30] - U.S. revenue was $46.4 million, reflecting a growth of 22.8% [31] - Adjusted EBITDA was positive at $1 million, compared to an adjusted EBITDA loss of $2.7 million in the prior year [34] - Net loss narrowed to $6.2 million or $0.14 per diluted share, compared to a net loss of $8.9 million or $0.22 per diluted share in the prior year [34] - Cash and marketable securities increased to $145.5 million, marking the first quarter of cash flow breakeven [35] Business Line Data and Key Metrics Changes - U.S. procedure volume increased by 25%, with double-digit growth across all modalities [10][32] - The physician base grew by 25%, reaching a record of 1,440 U.S. physicians performing procedures [22] - Average territory productivity reached $2.1 million, representing a 23% increase year-over-year [25] Market Data and Key Metrics Changes - International revenue was $2.2 million, impacted by delayed regulatory clearance for iFuse Torque in Europe [32] - The company expects iFuse Torque to boost revenue growth in Europe starting in 2026 [32] Company Strategy and Development Direction - The company aims to expand its platform of solutions targeting challenging procedures, improving surgical outcomes with lower failure rates [6][8] - Focus on innovation, physician engagement, commercial execution, and operational excellence as key priorities [12] - Plans to launch new products targeting outpatient settings and expand into new addressable markets [21][86] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand across the portfolio and the effectiveness of their strategy [44] - The company anticipates continued growth driven by strong physician engagement and product adoption [80] - Guidance for full-year revenue was updated to $195 million to $198 million, implying year-over-year growth of approximately 17% to 18% [36] Other Important Information - The company achieved cash flow breakeven ahead of schedule, indicating potential for consistent positive free cash flow [35] - Leadership changes were announced, with Tony Recoupero retiring and Nicholas Kerr promoted to Chief Commercial Officer [27][28] Q&A Session Summary Question: Guidance on top line growth and assumptions for the second half - Management highlighted strong first-half performance and confidence in continued demand, with a sequential decline expected in Q3 due to seasonality [40][46] Question: Gross margin guidance and pricing pressure - Management discussed maintaining gross margin guidance at 78.5% to 79%, embedding assumptions for ASP pressure while acknowledging potential for better-than-expected outcomes [51][56] Question: Growth of interventional doctors using products - Management noted strong growth from interventional doctors and the potential for further engagement with new product launches [60][62] Question: International market contribution and torque rollout in Europe - Management expressed optimism about the torque product's impact in Europe, with expectations for growth in 2026 [95] Question: Capital deployment priorities - Management indicated a focus on continued investment in R&D and commercial initiatives while maintaining a strong cash position [98]

Financial Data and Key Metrics Changes - Vertex Pharmaceuticals reported total revenue of $2,960,000,000 for Q2 2025, reflecting a 12% increase compared to Q2 2024 [5][41] - Non-GAAP operating income for Q2 2025 was $1,330,000,000, a significant recovery from a non-GAAP operating loss of $3,150,000,000 in Q2 2024 [44] - Net income for Q2 2025 was $1,200,000,000, compared to a net loss of $3,300,000,000 in the same quarter of the previous year [44] - Non-GAAP earnings per share were $4.52, a turnaround from a loss per share of $12.83 in Q2 2024 [44] Business Line Data and Key Metrics Changes - The CF franchise continued to perform strongly, with revenue growth driven by ongoing patient demand and the launch of new products [41][42] - CASJEVY contributed $30,000,000 to total revenue, while GERNAVIX added $12,000,000 [42] - The company is focused on expanding its CFTR modulator portfolio to younger age groups and developing new regimens [12][29] Market Data and Key Metrics Changes - Revenue outside the U.S. increased by 8% year-on-year, supported by healthy CF growth and contributions from CASJEVY [42] - The company has secured reimbursement for AlifTrek in multiple regions, including the U.S., U.K., EU, and Canada [11][12] Company Strategy and Development Direction - Vertex is focused on commercialization across multiple disease areas and expanding patient reach through new product launches [5][6] - The company is advancing its R&D pipeline with four programs in pivotal development and plans to initiate a fifth program in primary membranous nephropathy [6][20] - Vertex aims to secure DPN as its first PNP indication while continuing discussions with the FDA for broader indications [60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong revenue growth in 2025, reiterating guidance for total revenue between $11.85 billion and $12 billion [45][47] - The company anticipates continued growth from its CF medicines and expects to see increased revenue contributions from GERNAVIX in the second half of the year [46][47] Other Important Information - Vertex announced a new $4,000,000,000 share repurchase program, building on an existing program [44] - The company is preparing for multiple regulatory submissions in 2026 and early 2027, with several Phase III programs underway [27][28] Q&A Session Summary Question: On pain and GERNAVIX commercialization efforts - Management indicated that the increase in commercial efforts for GERNAVIX was a reaction to positive feedback and payer coverage progress [54] Question: Strategy for pain indications and gross to net expectations - The company plans to secure the DPN indication first and then explore broader indications, with gross to net expected to normalize as patient support programs are phased out [62] Question: Insights on GERNAVIX real-world evidence generation - Progress in real-world evidence generation is going well, with hospitals and health systems adopting GERNAVIX faster than expected [75] Question: Plans for POVY and prioritization of indications - The company plans to launch POVY with an auto injector for IGAN and prioritize indications based on unmet need and emerging data [80][82] Question: Commercial lives with unrestricted access for GERNAVIX - Management is working on expanding payer coverage and expects to see increased access as negotiations progress [94]

Core Insights - Pagaya Technologies Ltd. (PGY) is set to announce its second-quarter 2025 earnings on August 7, with expectations of strong performance based on previous results [1][5] - The Zacks Consensus Estimate for PGY's second-quarter revenues is $323.8 million, reflecting a 29.4% year-over-year increase [2][5] - The company has seen an 11.3% upward revision in earnings estimates for the upcoming quarter, with expected earnings per share (EPS) of 69 cents [2][5] Revenue and Earnings Estimates - Total revenues and other income for PGY are anticipated to be between $290 million and $310 million, supported by improved economics in personal loan and auto verticals [7][8] - Fee revenues are expected to reach $306 million, indicating a 25.9% year-over-year rise [4][5] - The network volume is estimated at $2.53 billion, which represents a 10% growth from the prior-year quarter [6] Earnings Surprise History - Pagaya has a mixed earnings surprise history, having outperformed the Zacks Consensus Estimate in only two of the last four quarters, with an average surprise of 12.9% [3][4] Growth Strategy - The company's growth strategy includes expanding product offerings, enhancing monetization of existing partnerships, and adding new enterprise lending partners, particularly large U.S. banks and auto captives [7][18] Market Performance and Valuation - PGY shares have outperformed the S&P 500 Index and key peers like LendingTree and LendingClub in the second quarter [11] - The stock is currently trading at a trailing 12-month price/book (P/B) ratio of 5.00X, which is above the industry average of 3.58X [15][17] Business Model Resilience - Pagaya's business model is characterized by its adaptability, having diversified beyond personal loans into auto lending and point-of-sale financing, which reduces exposure to cyclical risks [18] - The company has established a robust network of over 135 institutional funding partners to support its asset-backed securities, enhancing liquidity stability [19]